EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models

Artelo Biosciences, Inc. ARTL on Monday announced new research published in the peer-reviewed Journal of Investigative Dermatology describing the positive effects of ART26.12 in both in vitro and in vivo psoriasis models.

The research shows results comparable to immunomodulatory drugs with known serious adverse events.

The research highlights ART26.12, Artelo’s orally active, small-molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5), and its potential ability to treat psoriasis.

Also Read: Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

George Warren, PhD, Lead Author and Principal Scientist at Artelo, said, “We are excited to share the results on this novel target in psoriasis. Our findings demonstrate that ART26.12 has effects comparable to powerful immunomodulators, while its unique pharmacology leads to a significantly distinct expression of proteins and lipids in the skin.”

Dr. Warren added, “Pre-clinical IND-enabling studies with ART26.12, supported by a literature review of greater than 300 studies examining FABP inhibition, imply a low toxicological risk for ART26.12, which, if borne out in clinical studies, suggest FABP5 inhibition with an orally delivered small molecule may be an attractive, less costly, and safer approach for treating this debilitating chronic disease.”

A Phase 1 Single Ascending Dose study in healthy volunteers with ART26.12 has completed enrollment, and data announcements are expected in the second quarter of 2025.

The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN).

In addition to ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.

In January, Artelo Biosciences completed a safety review of the first cohort of eight healthy volunteers in the company’s Phase 1 study of ART26.12.

In December, Artelo Biosciences announced the presentation of preliminary data on ART27.13, a benzimidazole derivative being studied for cancer-related anorexia.

Artelo is evaluating ART27.13 in the Phase 1/2 trial in cancer-related anorexia, which is currently enrolling Phase 2 of the study.

In Phase 1, ART27.13 was orally administered at 150 to 650 microgram doses.

The investigational drug was well tolerated, with only mild to moderate adverse events observed in a minority of participants.

At one month of treatment, two-thirds of participants showed evidence that the drug was impacting their weight loss, with either stabilization or reversal of weight loss associated with their cancer.

Phase 2 is accruing participants at a 650 microgram dosage with planned escalation at 4-week intervals up to a dose of 1300 micrograms per day. Initial data from the Phase 2 CAReS trial is anticipated by the end of Q2 2025.

Price Action: ARTL stock closed at $1.04 on Friday.

Read Next: